Navigation Links
GW Pharmaceuticals Commences Phase 1b/2a Clinical Trial for the Treatment of Glioblastoma Multiforme (GBM)
Date:11/11/2013

LONDON, Nov. 11, 2013 /PRNewswire/ -- GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW") a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today it has commenced a Phase 1b/2a clinical trial for the treatment of Recurrent Glioblastoma Multiforme (GBM).

Glioma describes any tumor that arises from the glial tissue of the brain. GBM is a particularly aggressive tumor that forms from abnormal growth of glial tissue. According to the New England Journal of Medicine, GBM accounts for approximately 50% of the 22,500 new cases of brain cancer diagnosed in the United States each year. Treatment options are limited and expected survival is a little over one year. GBM is considered a rare, or orphan, disease by the FDA and the European Medicines Agency, or EMA.

This study follows several years of pre-clinical research conducted by GW in the field of glioma which has demonstrated that cannabinoids inhibit the viability of glioma cells both in vitro and in vivoi,ii via apoptosis or programmed cell death, may also affect angiogenesis, and have demonstrated tumor growth-inhibiting action and an improvement in the therapeutic efficacy of temozolomide, a standard treatment for glioma. In addition, GW has shown tumor response to be positively associated with tissue levels of cannabinoids. GW has identified the putative mechanism of action for our cannabinoid product candidate, where autophagy and programmed cell death are stimulated via stimulation of the TRB3 pathway.

"We are very excited about moving this compound into further human study and the prospects of cannabinoids as new anti-cancer treatments. This is GW's first clinical study of cannabinoids as a potential treatment to inhibit tumor growth," stated Dr. Stephen Wri
'/>"/>

SOURCE GW Pharmaceuticals plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... 2014 The report "Unmanned Ground ... Security), Technology, Payload, Type & by Geography - ... global unmanned ground vehicle market into various sub ... market sizes. The report also identifies the factors ... it along with the adoption trends. , The ...
(Date:10/18/2014)... (PRWEB) October 19, 2014 The ... (Short Acting, Intermediate Acting, Premixed), Modern Human Insulin ... Apidra, Levemir, NovoRapid, Novomix, Tresiba, Others) - Forecast ... major drivers, restraints, challenges, opportunities, current market trends, ... along with the estimates and forecasts of the ...
(Date:10/18/2014)... The report "1,6-Hexanediol Market by Application ... 2019", analyzes the global market on the basis ... industry details such as the key drivers, current ... , Browse 81 Market Data Tables and 29 ... on “1,6-Hexanediol Market by Application and by Geography ...
(Date:10/18/2014)... 2014 The Asia-Pacific hardware encryption display ... Asia-Pacific with analysis and forecast of revenue. This market ... to reach $51,362.6 million by 2018, at a CAGR ... the TOC of the Asia-Pacific hardware encryption market report, ... This also provides a glimpse of the segmentation of ...
Breaking Biology Technology:Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 2Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 3Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 4Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 5Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 2Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 3Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 51,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 21,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 31,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 41,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 5The Asia-Pacific hardware encryption display market is expected to reach $51,362.6 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific hardware encryption display market is expected to reach $51,362.6 million by 2018 - New Report by MicroMarket Monitor 3
... , ... , , , , ... 2100 bioanalyzer can,be used in combination with Standardized RT (StaRT)-PCR ... obtain highly reproducible, standardized gene expression,measurement with RT-PCR. The internal ...
... , , ... , , , This Application ... kit can be used to detect cell surface,and intracellular protein targets ... staining on CCRF-CEM cells and intracellular,glucocorticoid receptor (GR) staining of H4 ...
... , ... , , This Application Note describes ... be used to determine the efficiency,of transfection of mammalian cells using ... with,expression vectors encoding GFP from two different sources, and optimization,of transfection ...
Cached Biology Technology:Quantitative end-point RT-PCR gene,expression measurement using the,Agilent 2100 Bioanalyzer and,standardized RT-PCR 2Quantitative end-point RT-PCR gene,expression measurement using the,Agilent 2100 Bioanalyzer and,standardized RT-PCR 3Quantitative end-point RT-PCR gene,expression measurement using the,Agilent 2100 Bioanalyzer and,standardized RT-PCR 4Quantitative end-point RT-PCR gene,expression measurement using the,Agilent 2100 Bioanalyzer and,standardized RT-PCR 5Quantitative end-point RT-PCR gene,expression measurement using the,Agilent 2100 Bioanalyzer and,standardized RT-PCR 6Quantitative end-point RT-PCR gene,expression measurement using the,Agilent 2100 Bioanalyzer and,standardized RT-PCR 7Detection of antibody-stained cell,surface and intracellular protein targets,with the Agilent 2100 bioanalyzer 2Detection of antibody-stained cell,surface and intracellular protein targets,with the Agilent 2100 bioanalyzer 3Detection of antibody-stained cell,surface and intracellular protein targets,with the Agilent 2100 bioanalyzer 4Detection of antibody-stained cell,surface and intracellular protein targets,with the Agilent 2100 bioanalyzer 5Detection of antibody-stained cell,surface and intracellular protein targets,with the Agilent 2100 bioanalyzer 6Detection of antibody-stained cell,surface and intracellular protein targets,with the Agilent 2100 bioanalyzer 7Detection of antibody-stained cell,surface and intracellular protein targets,with the Agilent 2100 bioanalyzer 8Monitoring transfection efficiency by,green fluorescent protein (GFP) detection,with the Agilent 2100 bioanalyzer 2Monitoring transfection efficiency by,green fluorescent protein (GFP) detection,with the Agilent 2100 bioanalyzer 3Monitoring transfection efficiency by,green fluorescent protein (GFP) detection,with the Agilent 2100 bioanalyzer 4Monitoring transfection efficiency by,green fluorescent protein (GFP) detection,with the Agilent 2100 bioanalyzer 5Monitoring transfection efficiency by,green fluorescent protein (GFP) detection,with the Agilent 2100 bioanalyzer 6Monitoring transfection efficiency by,green fluorescent protein (GFP) detection,with the Agilent 2100 bioanalyzer 7
(Date:10/15/2014)... virus is spreading rapidly and to an unexpected extent. ... the past and the virus shows a new disease ... before. For this reason, the German National Academy of ... and Engineering, and the Union of the German Academies ... the Ebola epidemic today. , In the statement the ...
(Date:10/14/2014)... Like discriminating thieves, prostate cancer tumors scavenge and hoard ... But such avarice may be a fatal weakness. ... to kill prostate cancer cells by delivering a trove ... the diseased cells brimming with the mineral, leaving non-cancer ... drugs already commercially available for other uses, could soon ...
(Date:10/14/2014)... research team has discovered a new kind of stem cell ... that lines liver blood vessels, according to a study published ... existence of such a cell type contradicts current theory on ... may hold clues to origins of, and future treatment for, ... single cell into a complex being made up of more ...
Breaking Biology News(10 mins):Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5Prostate cancer's penchant for copper may be a fatal flaw 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 3
... scientists at the University of Minnesota Medical School and ... and made suggestions on how to advance research and ... published in the January 2008 issue of the Lancet ... , Many neurological disorders are difficult to treat because ...
... and the National Center for Ecological Analysis and Synthesis ... predict gene flow across landscapes. Their approach could give ... for wildlife corridors, which are crucial to protecting biodiversity. ... theory and ecological connectivity, said Brad McRae, head of ...
... the University of California, San Diego have discovered a ... in the gene are present in both the female ... a paper that appears online today in the journal ... consent mutation because of its unusual properties. Mutations ...
Cached Biology News:International scientists tackle obstacles to treating brain disorders 2International scientists tackle obstacles to treating brain disorders 3Model connects circuit theory to wildlife corridors 2Biologists find unusual plant gene: abstinence by mutual consent 2Biologists find unusual plant gene: abstinence by mutual consent 3
... Error-free cloning of BAC (100+kb), fosmid ... Greater insert stability than any othe BAC ... for high yields and easy recombinant DNA ... or transcription-free (pSMART VC) vectors for the ...
Anti-Goat HRP-DAB Cell & Tissue Staining Kit...
CHIMAERIC HUMAN IgA2 ANTI NP...
... Cloning Kit includes the pZErO-2 ... selection in E. coli. The ... to eliminate high background. The ... reagents you need for simple ...
Biology Products: